Medicenna Presents Preclinical Data On MDNA113, Its Targeted Metalloprotease Activated SuperKine At The 38th Annual Meeting Of The Society For Immunotherapy Of Cancer
Portfolio Pulse from Benzinga Newsdesk
Medicenna Therapeutics Corp. (TSX:MDNA) presented new preclinical data on its T-MASK platform and MDNA113, a first-in-class IL-13R⍺2 targeted therapy, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data shows the platform's ability to enhance tumor specific accumulation, increase anti-tumor activity, and improve the safety profile of immune modulators. MDNA113 is designed to deliver bispecific IL-2-antiPD1 Superkine to cancers that express the tumor associate antigen, IL-13R⍺2, which is linked to aggressive cancers affecting over 2 million patients annually.
November 03, 2023 | 4:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicenna's new preclinical data on its T-MASK platform and MDNA113 shows potential for treating aggressive cancers. This could lead to increased interest in the company's stock.
The positive preclinical data on Medicenna's T-MASK platform and MDNA113 demonstrates the company's potential in developing effective cancer treatments. This could attract more investors, potentially driving up the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100